Ado‐trastuzumab emtansine (T‐DM1) consists of a humanized anti‐HER2 IgG1 antibody known as trastuzumab, which was introduced in 1998 for the treatment of HER2+ breast cancers. This evidence concerns the gene ERBB2 and breast carcinoma.